Published in FASEB J on September 27, 2010
Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med (2012) 3.98
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener (2012) 2.11
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.62
Tunneling nanotubes spread fibrillar α-synuclein by intercellular trafficking of lysosomes. EMBO J (2016) 1.56
Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol (2012) 1.46
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42
Soluble α-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci (2012) 1.34
Exosomes: vesicular carriers for intercellular communication in neurodegenerative disorders. Cell Tissue Res (2012) 1.31
A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ (2011) 1.27
Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis (2012) 1.25
Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer's disease brain. Nat Commun (2015) 1.23
Assessment of α-synuclein secretion in mouse and human brain parenchyma. PLoS One (2011) 1.19
Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One (2012) 1.15
Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res (2011) 1.15
Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol (2011) 1.13
Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev (2014) 1.10
Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics (2014) 1.09
Hsc70 protein interaction with soluble and fibrillar alpha-synuclein. J Biol Chem (2011) 1.07
Characterization of oligomer formation of amyloid-beta peptide using a split-luciferase complementation assay. J Biol Chem (2011) 1.05
Tau enhances α-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One (2011) 1.04
Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies. Brain (2015) 1.03
Targeting protein aggregation for the treatment of degenerative diseases. Nat Rev Drug Discov (2015) 1.02
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol (2014) 1.01
α-Synuclein: the long distance runner. Brain Pathol (2013) 0.99
α-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J Biol Chem (2013) 0.98
TDP-43 is intercellularly transmitted across axon terminals. J Cell Biol (2015) 0.97
Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment. Autophagy (2014) 0.96
Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease. J Cell Physiol (2015) 0.96
α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem (2011) 0.96
The H50Q mutation enhances α-synuclein aggregation, secretion, and toxicity. J Biol Chem (2014) 0.96
Lipid peroxidation product 4-hydroxy-2-nonenal promotes seeding-capable oligomer formation and cell-to-cell transfer of α-synuclein. Antioxid Redox Signal (2012) 0.93
Melittin restores proteasome function in an animal model of ALS. J Neuroinflammation (2011) 0.91
Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat (2014) 0.90
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics (2016) 0.90
Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization. Ann Neurol (2014) 0.90
Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation. Acta Neuropathol (2015) 0.90
Barcoding heat shock proteins to human diseases: looking beyond the heat shock response. Dis Model Mech (2014) 0.90
Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet (2014) 0.90
Identification of protein interfaces between α-synuclein, the principal component of Lewy bodies in Parkinson disease, and the molecular chaperones human Hsc70 and the yeast Ssa1p. J Biol Chem (2012) 0.89
Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun (2013) 0.89
Prions and Protein Assemblies that Convey Biological Information in Health and Disease. Neuron (2016) 0.87
Protein Quality Control by Molecular Chaperones in Neurodegeneration. Front Neurosci (2017) 0.87
Activation of MyD88-dependent TLR1/2 signaling by misfolded α-synuclein, a protein linked to neurodegenerative disorders. Sci Signal (2015) 0.87
α-synuclein interacts with SOD1 and promotes its oligomerization. Mol Neurodegener (2015) 0.85
pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers. Proc Natl Acad Sci U S A (2015) 0.84
Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation. Exp Neurobiol (2014) 0.84
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. J Neuroinflammation (2015) 0.84
Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord (2014) 0.84
Relationship of neighboring tissue and gliosis to α-synuclein pathology in a fetal transplant for Parkinson's disease. Am J Neurodegener Dis (2012) 0.83
Chaperones in Neurodegeneration. J Neurosci (2015) 0.83
Sequence-dependent internalization of aggregating peptides. J Biol Chem (2014) 0.82
Molecular chaperones and co-chaperones in Parkinson disease. Neuroscientist (2012) 0.82
Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies. Acta Neuropathol Commun (2013) 0.82
β1-integrin-dependent migration of microglia in response to neuron-released α-synuclein. Exp Mol Med (2014) 0.82
Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention. J Alzheimers Dis Parkinsonism (2013) 0.81
Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapy. Clin Dev Immunol (2013) 0.81
Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. PLoS One (2014) 0.81
Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies. Expert Opin Ther Targets (2015) 0.80
Molecular chaperones in Parkinson's disease--present and future. J Parkinsons Dis (2011) 0.80
Functionally different α-synuclein inclusions yield insight into Parkinson's disease pathology. Sci Rep (2016) 0.80
Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease. Prion (2012) 0.79
Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases. Neurotherapeutics (2013) 0.79
Molecular chaperones, α-synuclein, and neurodegeneration. Mol Neurobiol (2012) 0.79
Combination therapies: The next logical Step for the treatment of synucleinopathies? Mov Disord (2015) 0.79
Transmission of Soluble and Insoluble α-Synuclein to Mice. J Neuropathol Exp Neurol (2015) 0.78
Therapeutic approaches in Parkinson's disease and related disorders. J Neurochem (2016) 0.78
Drug targets from genetics: α-synuclein. CNS Neurol Disord Drug Targets (2011) 0.78
Tunneling nanotubes: A possible highway in the spreading of tau and other prion-like proteins in neurodegenerative diseases. Prion (2016) 0.78
Extracellular ATP induces intracellular alpha-synuclein accumulation via P2X1 receptor-mediated lysosomal dysfunction. Neurobiol Aging (2014) 0.77
Sequence complexity of amyloidogenic regions in intrinsically disordered human proteins. PLoS One (2014) 0.77
Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease. Small GTPases (2016) 0.77
Direct visualization of CHIP-mediated degradation of alpha-synuclein in vivo: implications for PD therapeutics. PLoS One (2014) 0.76
Potential Modes of Intercellular α-Synuclein Transmission. Int J Mol Sci (2017) 0.76
Mechanism of Anti-α-Synuclein Immunotherapy. J Mov Disord (2016) 0.76
Non-cell-autonomous Neurotoxicity of α-synuclein Through Microglial Toll-like Receptor 2. Exp Neurobiol (2016) 0.76
Disease-modifying therapeutic directions for Lewy-Body dementias. Front Neurosci (2015) 0.76
The neural chaperone proSAAS blocks α-synuclein fibrillation and neurotoxicity. Proc Natl Acad Sci U S A (2016) 0.76
Cellular Uptake of α-Synuclein Oligomer-Selective Antibodies is Enhanced by the Extracellular Presence of α-Synuclein and Mediated via Fcγ Receptors. Cell Mol Neurobiol (2016) 0.76
Dysregulation of autophagy and mitochondrial function in Parkinson's disease. Transl Neurodegener (2016) 0.75
The chaperonin CCT inhibits assembly of α-synuclein amyloid fibrils by a specific, conformation-dependent interaction. Sci Rep (2017) 0.75
More than a Rumor Spreads in Parkinson's Disease. Front Hum Neurosci (2016) 0.75
Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff. J Parkinsons Dis (2017) 0.75
Investigation of Endocytic Pathways for the Internalization of Exosome-Associated Oligomeric Alpha-Synuclein. Front Neurosci (2017) 0.75
Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation. Age (Dordr) (2015) 0.75
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun (2017) 0.75
A Rapid, Semi-Quantitative Assay to Screen for Modulators of Alpha-Synuclein Oligomerization Ex vivo. Front Neurosci (2016) 0.75
The Oligomer Hypothesis in α-Synucleinopathy. Neurochem Res (2017) 0.75
The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion. Aging (Albany NY) (2017) 0.75
Possible Function of Molecular Chaperones in Diseases Caused by Propagating Amyloid Aggregates. Front Neurosci (2017) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods (2005) 7.62
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science (2001) 6.15
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Visualization of molecular interactions by fluorescence complementation. Nat Rev Mol Cell Biol (2006) 3.79
A highly sensitive protein-protein interaction assay based on Gaussia luciferase. Nat Methods (2006) 3.73
Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol (2009) 3.55
Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A (2009) 3.47
Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron (2005) 3.20
Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci (2007) 3.16
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 2.96
Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem (2005) 2.64
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci (2008) 2.51
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes. J Immunol (2006) 2.13
Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol (2007) 2.08
In vitro studies show that Hsp70 can be released by glia and that exogenous Hsp70 can enhance neuronal stress tolerance. Brain Res (2001) 2.07
Selective release from cultured mammalian cells of heat-shock (stress) proteins that resemble glia-axon transfer proteins. J Cell Physiol (1989) 2.04
Expression of the molecular chaperone Hsp70 in detergent-resistant microdomains correlates with its membrane delivery and release. J Biol Chem (2003) 2.02
Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett (2000) 1.98
Hsp70 translocates into the plasma membrane after stress and is released into the extracellular environment in a membrane-associated form that activates macrophages. J Immunol (2008) 1.95
Patterned cell culture inside microfluidic devices. Lab Chip (2004) 1.89
Pharmacological prevention of Parkinson disease in Drosophila. Nat Med (2002) 1.84
Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J Biol Chem (2004) 1.79
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
Microfluidic Multicompartment Device for Neuroscience Research. Langmuir (2003) 1.72
Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem (2009) 1.67
Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol (1998) 1.67
Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. J Biol Chem (2004) 1.60
Hsp70 release from peripheral blood mononuclear cells. Biochem Biophys Res Commun (2004) 1.58
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem (2007) 1.55
Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species. J Biol Chem (2005) 1.48
Exercise induces hepatosplanchnic release of heat shock protein 72 in humans. J Physiol (2002) 1.45
CHIP targets toxic alpha-Synuclein oligomers for degradation. J Biol Chem (2008) 1.43
Mechanisms for Hsp70 secretion: crossing membranes without a leader. Methods (2007) 1.42
Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nat Med (2000) 1.39
Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther (2009) 1.38
Beta-synuclein inhibits formation of alpha-synuclein protofibrils: a possible therapeutic strategy against Parkinson's disease. Biochemistry (2003) 1.36
Stress-induced release of HSC70 from human tumors. Cell Immunol (2003) 1.36
Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol (2005) 1.34
A cDNA library functional screening strategy based on fluorescent protein complementation assays to identify novel components of signaling pathways. Methods (2004) 1.33
Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun (2004) 1.30
Heat shock-like protein is transferred from glia to axon. Brain Res (1986) 1.30
Rab11a and HSP90 regulate recycling of extracellular alpha-synuclein. J Neurosci (2009) 1.21
Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J Neurochem (2009) 1.17
Cat exposure induces both intra- and extracellular Hsp72: the role of adrenal hormones. Psychoneuroendocrinology (2004) 1.00
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A (2003) 8.92
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell (2011) 6.23
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci (2005) 4.71
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol (2002) 4.42
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (2013) 3.59
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (2002) 3.48
Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron (2008) 3.46
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
Atomic view of a toxic amyloid small oligomer. Science (2012) 3.13
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem (2003) 3.00
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol (2006) 2.93
Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry (2004) 2.70
Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science (2009) 2.65
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron (2004) 2.53
Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci (2006) 2.47
Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 2.47
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord (2003) 2.12
Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol Neurodegener (2012) 2.11
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem (2005) 2.08
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
Retracted SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci (2012) 2.00
Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci (2004) 1.99
Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci (2009) 1.99
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry (2007) 1.88
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem (2005) 1.85
Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci (2003) 1.85
Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci (2006) 1.83
Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proc Natl Acad Sci U S A (2003) 1.81
Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci (2003) 1.81
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett (2002) 1.79
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci (2008) 1.77
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol (2003) 1.73
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci (2005) 1.70
Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol (2007) 1.69
Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci (2009) 1.68
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. J Cell Biol (2009) 1.68
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J (2006) 1.66
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Inhibition of the NFAT pathway alleviates amyloid β neurotoxicity in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.64
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun (2009) 1.63
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl (2005) 1.60